The main objective of this study was to assess preferences for involvement in treatment decisions and requests for prognostic information in newly diagnosed higher-risk myelodysplastic syndrome (MDS) patients.
introduction Clinical decision-making in patients with myelodysplastic syndromes (MDSs) is challenging [1] . Treatment recommendations for these patients may range from highly intensive treatments to best supportive care [2] . Prognosis of MDS is routinely assessed by an international prognostic scoring system (IPSS) which distinguishes among four subgroups of patients, namely of low, intermediate-1, intermediate-2 and high risk. Patients with intermediate-2 and high-IPSS risk (i.e. higher-risk patients) often progress rapidly to acute myeloid leukemia and have poor prognosis [3] . The IPSS has been recently revised stratifying patients with even greater prognostic power [4] . Also, the majority of these patients are diagnosed at an older age [5] and suffer from a broad range of burdensome symptoms impacting their health-related quality of life (HRQOL) [6, 7] .
In higher-risk MDS, the patient's personal preference for the type of therapy should be highly considered [2] . The shared decision-making model, where clinicians and patients make decisions together, should be seen as the preferred approach to determine patients' treatment in medical care [8] . However, empirical evidence has shown that some patients might want to engage more actively in making treatment decisions with their physicians, whereas others might prefer a more passive role [9] [10] [11] .
Also, previous studies have shown that higher-risk MDS patients highly value HRQOL issues and pointed out the importance of investigating how patient's HRQOL relates to treatment choices at the time of diagnosis [12] .
Another issue to be addressed during initial consultation with newly diagnosed higher-risk MDS patients is that of conveying prognostic information. Physicians often face challenges in discussing patients' prognosis, particularly in the setting of advanced cancer populations [13, 14] . Thus, understanding the extent to which higher-risk MDS patients wish to be involved in making treatment decisions and whether they wish to receive prognostic information has major clinical implications.
The two main objectives of this study were to assess preferences for involvement in treatment decisions and whether patients requested prognostic information on survival to their physician in newly diagnosed higher-risk MDS patients. Key sociodemographic and clinical factors investigated for their possible relationship with preferences were selected based on previous literature in other cancer populations [10, 11] and on clinical relevance for high-risk MDS. A tertiary objective was to explore relationships between patients' preferences and their HRQOL profile.
patients and methods

study design and study population
This was an international prospective cohort observational study that consecutively enrolled patients from November 2008 through August 2012. Patients were recruited in 37 centers from nine countries (Austria, Belgium, China, Czech Republic, France, Germany, Italy, the UK and the USA). All patients were classified according to the World Health Organization (WHO) classification [15] . The patients were eligible if they had been diagnosed with MDS with IPSS risk score of intermediate-2 or high risk, within 6 months before the date of registration. Patients evolving from a lower risk score category (i.e. IPSS low and intermediate-1 risk score) were also eligible. Baseline assessment of patientreported HRQOL and preference for involvement in treatment decisions was mandatory to be included in this study. The protocol specified that such assessment would take place after having had at least one encounter with the treating physician, discussing treatment options and before treatment initiation for higher-risk MDS. Exclusion criteria included the following: having received any kind of therapy (other than red blood cell-RBC-or platelet transfusions) and having any kind of psychiatric disorder or major cognitive dysfunction hampering a self-reported evaluation. Patients with secondary MDS were not included.
The study was approved by all Ethic Committees of each participating center, and all patients provided written informed consent. This study was registered on the US National Cancer Institute website (http://clinicaltrials. gov/); NCT00809575.
preference for involvement in treatment decisions and request for prognostic information
The control preference scale [9] was used to assess patient preferences. This is a validated scale to assess preferred roles in healthcare decisions [9, 16] . Patients themselves selected one of five statements (supplementary Table S1 , available at Annals of Oncology online) that best reflect their preference for involvement in treatment decisions. According to this scale, patients can be categorized into one of the following three broad groups, indicating different attitude roles in the clinical decision-making process: active, collaborative/ shared or passive. The latter one indicates those patients who prefer to leave decisions on the most appropriate treatment option to their physician. Whether patients requested prognostic information on survival during consultation was also assessed by asking physicians. The number of physicianpatient encounters was collected. [17] .
variables examined for the relationship with preference for involvement and request of prognostic information
Based on previous work [10, 11] [18] . Hemoglobin (Hb) level, per se, was also considered due to its additive prognostic value to the IPSS for survival [19] . Comorbidity (one or more versus no comorbidity) was assessed with the hematopoietic cell transplantation-specific comorbidity index [20] . Time from diagnosis of higher-risk MDS to patient survey completion was also taken into account.
statistical analysis
We investigated the relationship of a preferred role and information request with previously mentioned patients' sociodemographic and clinical characteristics, by χ 2 , Wilcoxon-Mann-Whitney and Kruskal-Wallis tests as appropriate (α = 0.05). Based on clinical relevance, we chose to examine the impact of patients' characteristics on the probability of preferring a passive role and of not-requesting prognostic information. For this purpose, a multivariate multilevel logistic regression analysis was carried out (α = 0.05), accounting for the clustered nature of the data (i.e. each physician could evaluate more than one patient) [21] . Variables were checked for possible multicollinearity by the variance inflation factor. Based on multivariate analysis results and for descriptive purposes, the distributions of Hb values for both groups (i.e. passive versus collaborative/active) were investigated by the empirical quantile plot. Additional analyses were carried out by a χ 2 test, to evaluate possible differences in a preferred role and request for prognostic information, between the country enrolling the most (i.e. Italy) and other countries (α = 0.05). The same test was used to assess the association between number of encounters discussing treatment options with physicians and patients' preferences and request for prognostic information. The association between the patients' HRQOL profile and their preferred role and request for prognostic information was explored, and mean scores and effect sizes (ESs) were reported. All analyses were carried out with SAS Version 9.2 (SAS Institute Inc.).
results
A total of 280 patients were enrolled, and, of these, 176 (63%) were men and 104 (37%) were women. 
multivariate analysis on preference for involvement in treatment decisions
Half of the patients (N = 132, 47%) favored a passive role in treatment decision-making. Of the remaining patients, 39% favored a collaborative approach, and 14% favored an active role. Table 1 shows patients' characteristics by their preferred role. In univariate analysis, the Hb level, age and comorbidity were significantly different (P < 0.05) among groups. Multivariate analysis, however, revealed that patients with lower Hb levels were more likely to prefer a passive role [odds ratio (OR) = 0.839, 95% confidence intervals (CIs), 0.711-0.989; P = 0.037]. No other variables, including evolving from a lowerrisk category or living alone, had a statistically significant association with preference for a passive role in multivariate analysis. To further characterize the role of Hb in patients preferring a passive versus those preferring collaborative or active roles, we plotted the Hb quantiles for both groups (Figure 1) . Inspection of the plot shows that the maximum observable Hb value is generally lower in the passive group than it is in the active/collaborative group, for any given probability. multivariate analysis on request for prognostic information on survival Overall, 61% (N = 171) of patients requested prognostic information on survival from their physician during consultation. Patient characteristics by request for prognostic information are reported in Table 2 . Multivariate analysis showed that the likelihood of not requesting prognostic information was higher for older patients Active/Collaborative Passive 30% 40% 50% 60% 70% 80% 90% 100% Figure 1 . Empirical quantile plot of hemoglobin (Hb) levels by the preferred role in clinical decision-making. For each group, the plot shows the maximum observable level of Hb for any given probability. To illustrate, the maximum level of Hb observable with 80% probability is 10 g/dl in the passive group versus 11.3 g/dl in the active/collaborative group.
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(OR = 1.065; 95% CI, 1.023-1.110; P = 0.003) and for those with lower education (OR = 2.893; 95% CI, 1.298-6.448; P = 0.010).
additional analyses
Preference for involvement in treatment decisions and request of prognostic information were not statistically significant associated with the number of encounters with physicians. Also, we did not find any statistically significant country-related difference in preferred roles and request of prognostic information (data not shown).
HRQOL profile by preference for involvement in treatment decision and request of prognostic information
Despite no statistically significant differences among the three groups, a worse overall HRQOL profile was found for patients preferring a passive role. Figure 2 depicts the ES of patients original articles Annals of Oncology preferring an active versus those preferring a passive role when each group was compared with patients preferring a collaborative approach. Fatigue was the most compromised aspect in patients who preferred a passive role compared with those preferring a collaborative role (ES = 0.22). Patients who did not request prognostic information had statistically significant worse outcomes for physical functioning (P = 0.009), role functioning (P < 0.001) and fatigue (P = 0.007). HRQOL profiles of patients who requested prognostic information versus those who did not are displayed in supplementary Figure S1 , available at Annals of Oncology online.
discussion
Selecting the most appropriate treatment strategy for patients with advanced cancers can be crucial [22] . The way treatment decisions are taken and the degree of involvement that patients wish to have in this process is thus an important area of research.
The main finding of this study was that of showing, for the first time, that decision-making preferences vary among newly diagnosed higher-risk MDS patients. Also, the number of patients who preferred to leave treatment decisions to their physicians (47%) was remarkable. The main clinical implication of these data is that of raising physicians' awareness of the importance of openly discuss with their patients to what extent they desire to be involved.
The literature shows a great deal of variation in reporting the extent to which patients prefer to be involved [11] . Our findings of prevalence for a passive role are consistent with similar studies conducted in advanced cancer populations. Elkin et al. [10] , investigated this issue in a sample of 73 elderly advanced stage colorectal cancer patients. They found that 52% of their patients preferred a passive role at the time of diagnosis. Similar to our results, a passive role was more common in patients with poorer performance status and lower education. However, our multivariate analysis revealed that a lower Hb level was the only factor independently associated with a higher likelihood of preferring a passive role.
It is possible to speculate that patients with lower Hb represent a particularly debilitated subgroup and that this is somehow reflected in the way they engage in treatment discussions. This could be supported by previous data, indicating that low Hb is an important predictor of shorter survival in MDS [19] and in other diseases as well [23] . In addition, patients preferring a passive role reported a worse HRQOL profile than those preferring an active role (Figure 2) , and this might further suggest an association between a greater disease burden and a preference to leave treatment decisions to physicians. Weak correlations were found between Hb levels and all HRQOL scales in our sample (data not shown), suggesting that it is unlikely that the lower HRQOL profile of patients preferring a passive role merely reflected the influence of Hb. In a study conducted on 80 cancer patients with heterogeneous diagnoses [24] , it was found that patients whose condition had recently worsened were more likely to want progressively less involvement in decision-making.
Another key finding was that, despite their advanced disease stage, a large proportion of patients (61%) still wanted to receive prognostic information. These data parallel that obtained by Hagerty et al. [25] who showed that 59% of cancer patients wanted to discuss expected survival when first diagnosed with metastatic disease. We found that older patients and those with lower education were less likely to request prognostic information. This finding might help physicians to identify, early on, patients for whom an explicit discussion of prognosis might be most beneficial. The literature on predictors of prognostic information preferences in advanced cancer patients is scarce [13] ; however, previous data [26] seem to support the predictive value of both variables for the lack of request of prognostic information.
More research is needed to further ascertain which are the underlying reasons for preferring a passive role and for not requesting prognostic information in higher-risk MDS patients. Also, tactics and strategies to promote shared decision-making have been proposed [27] and future studies are necessary to investigate the value of these approaches in this population.
This study had limitations. Video recording of the physicianpatient encounter could have yielded full information on the content of the consultation, e.g. we do not know if the preferred role was actually attained by the patients. However, recording was not deemed feasible considering several logistical and administrative challenges across all participating centers. Also, although average compliance per center was 91%, there were 31 patients who refused to entry the study and we could only rely on the input of patients who agreed to participate.
Our study also had a number of strengths. Unlike previous studies investigating this issue [11] , we analyzed a large and homogenous (in terms of disease and risk category) inception cohort of patients and included in the analysis key clinical and laboratory data. Also, considering that higher-risk MDS is a rare disease population, the fact that patients for our study were accrued from several centers increases our confidence in the strength of the generalizability of our findings. Lastly, patients' preferences were elicited at the time of diagnosis of higher-risk MDS, which is a topical time point in the treatment pathway as important decisions are to be made. Thus, we also avoided possible assessment bias due to the experience of treatment outcomes [28] .
In conclusion, current findings show that decision-making preferences vary among patients with newly diagnosed higherrisk MDS and suggest that those with worse underlying health conditions are more likely to prefer less involvement in treatment decisions. Physicians are encouraged to explicitly discuss with their patients to what extent they desire to be involved to better respond to their needs and preferences.
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